Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Von Willebrand factor delays liver repair after acetaminophen-induced acute liver injury in mice.

Groeneveld D, Cline-Fedewa H, Baker KS, Williams KJ, Roth RA, Mittermeier K, Lisman T, Palumbo JS, Luyendyk JP.

J Hepatol. 2019 Oct 10. pii: S0168-8278(19)30600-2. doi: 10.1016/j.jhep.2019.09.030. [Epub ahead of print]

PMID:
31606553
2.

Direct Amplification of Tissue Factor:Factor VIIa Procoagulant Activity by Bile Acids Drives Intrahepatic Coagulation.

Baker KS, Kopec AK, Pant A, Poole LG, Cline-Fedewa H, Ivkovich D, Olyaee M, Woolbright BL, Miszta A, Jaeschke H, Wolberg AS, Luyendyk JP.

Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2038-2048. doi: 10.1161/ATVBAHA.119.313215. Epub 2019 Aug 15.

PMID:
31412737
3.

Dichotomous Role of Plasmin in Regulation of Macrophage Function after Acetaminophen Overdose.

Roth K, Strickland J, Joshi N, Deng M, Kennedy RC, Rockwell CE, Luyendyk JP, Billiar TR, Copple BL.

Am J Pathol. 2019 Oct;189(10):1986-2001. doi: 10.1016/j.ajpath.2019.07.003. Epub 2019 Aug 2.

PMID:
31381887
4.

Endothelial force awakens a mechanism of portal hypertension: It's a neutrophil extracellular trap!

Groeneveld DJ, Luyendyk JP.

J Thromb Haemost. 2019 Aug;17(8):1201-1204. doi: 10.1111/jth.14530. Epub 2019 Jun 28. No abstract available.

PMID:
31254323
5.

Intrahepatic fibrin(ogen) deposition drives liver regeneration after partial hepatectomy in mice and humans.

Groeneveld D, Pereyra D, Veldhuis Z, Adelmeijer J, Ottens P, Kopec AK, Starlinger P, Lisman T, Luyendyk JP.

Blood. 2019 Mar 14;133(11):1245-1256. doi: 10.1182/blood-2018-08-869057. Epub 2019 Jan 17.

PMID:
30655274
6.

The multifaceted role of fibrinogen in tissue injury and inflammation.

Luyendyk JP, Schoenecker JG, Flick MJ.

Blood. 2019 Feb 7;133(6):511-520. doi: 10.1182/blood-2018-07-818211. Epub 2018 Dec 6. Review.

PMID:
30523120
7.

Chronic liver injury drives non-traditional intrahepatic fibrin(ogen) crosslinking via tissue transglutaminase.

Poole LG, Pant A, Baker KS, Kopec AK, Cline-Fedewa HM, Iismaa SE, Flick MJ, Luyendyk JP.

J Thromb Haemost. 2019 Jan;17(1):113-125. doi: 10.1111/jth.14330. Epub 2018 Dec 10.

PMID:
30415489
8.

Role of the blood coagulation cascade in hepatic fibrosis.

Pant A, Kopec AK, Luyendyk JP.

Am J Physiol Gastrointest Liver Physiol. 2018 Aug 1;315(2):G171-G176. doi: 10.1152/ajpgi.00402.2017. Epub 2018 May 3. Review.

9.

Coagulation parameters following equine herpesvirus type 1 infection in horses.

Wilson ME, Holz CL, Kopec AK, Dau JJ, Luyendyk JP, Soboll Hussey G.

Equine Vet J. 2019 Jan;51(1):102-107. doi: 10.1111/evj.12843. Epub 2018 May 17.

PMID:
29658149
10.

Plasminogen Activator Inhibitor-1 Reduces Tissue-Type Plasminogen Activator-Dependent Fibrinolysis and Intrahepatic Hemorrhage in Experimental Acetaminophen Overdose.

Pant A, Kopec AK, Baker KS, Cline-Fedewa H, Lawrence DA, Luyendyk JP.

Am J Pathol. 2018 May;188(5):1204-1212. doi: 10.1016/j.ajpath.2018.01.010. Epub 2018 Feb 16.

11.

Caspase Inhibition Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo.

Kopec AK, Spada AP, Contreras PC, Mackman N, Luyendyk JP.

Toxicol Sci. 2018 Apr 1;162(2):396-405. doi: 10.1093/toxsci/kfx268.

12.

Platelets as Modulators of Liver Diseases.

Lisman T, Luyendyk JP.

Semin Thromb Hemost. 2018 Mar;44(2):114-125. doi: 10.1055/s-0037-1604091. Epub 2017 Sep 12. Review.

13.

Targeting Phospholipase D4 Attenuates Kidney Fibrosis.

Trivedi P, Kumar RK, Iyer A, Boswell S, Gerarduzzi C, Dadhania VP, Herbert Z, Joshi N, Luyendyk JP, Humphreys BD, Vaidya VS.

J Am Soc Nephrol. 2017 Dec;28(12):3579-3589. doi: 10.1681/ASN.2016111222. Epub 2017 Aug 16.

14.

Thrombin promotes diet-induced obesity through fibrin-driven inflammation.

Kopec AK, Abrahams SR, Thornton S, Palumbo JS, Mullins ES, Divanovic S, Weiler H, Owens AP 3rd, Mackman N, Goss A, van Ryn J, Luyendyk JP, Flick MJ.

J Clin Invest. 2017 Aug 1;127(8):3152-3166. doi: 10.1172/JCI92744. Epub 2017 Jul 24.

15.

Von Willebrand factor deficiency reduces liver fibrosis in mice.

Joshi N, Kopec AK, Ray JL, Cline-Fedewa H, Groeneveld DJ, Lisman T, Luyendyk JP.

Toxicol Appl Pharmacol. 2017 Aug 1;328:54-59. doi: 10.1016/j.taap.2017.05.018. Epub 2017 May 17.

16.

Plasminogen Activator Inhibitor-1 Is Critical in Alcohol-Enhanced Acute Lung Injury in Mice.

Poole LG, Massey VL, Siow DL, Torres-Gonzáles E, Warner NL, Luyendyk JP, Ritzenthaler JD, Roman J, Arteel GE.

Am J Respir Cell Mol Biol. 2017 Sep;57(3):315-323. doi: 10.1165/rcmb.2016-0184OC.

17.

Trichloroethylene Exposure Reduces Liver Injury in a Mouse Model of Primary Biliary Cholangitis.

Ray JL, Kopec AK, Joshi N, Cline-Fedewa H, Lash LH, Williams KJ, Leung PS, Gershwin ME, Luyendyk JP.

Toxicol Sci. 2017 Apr 1;156(2):428-437. doi: 10.1093/toxsci/kfw264.

18.

Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis.

Joshi N, Kopec AK, Cline-Fedewa H, Luyendyk JP.

Toxicology. 2017 Feb 15;377:73-80. doi: 10.1016/j.tox.2016.12.009. Epub 2016 Dec 31.

19.

Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte αMβ2 integrin-dependent upregulation of Mmp12.

Kopec AK, Joshi N, Cline-Fedewa H, Wojcicki AV, Ray JL, Sullivan BP, Froehlich JE, Johnson BF, Flick MJ, Luyendyk JP.

J Hepatol. 2017 Apr;66(4):787-797. doi: 10.1016/j.jhep.2016.12.004. Epub 2016 Dec 10.

20.

From the Cover: Coagulation-Driven Hepatic Fibrosis Requires Protease Activated Receptor-1 (PAR-1) in a Mouse Model of TCDD-Elicited Steatohepatitis.

Nault R, Fader KA, Kopec AK, Harkema JR, Zacharewski TR, Luyendyk JP.

Toxicol Sci. 2016 Dec;154(2):381-391. Epub 2016 Sep 9.

21.

Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis.

Joshi N, Ray JL, Kopec AK, Luyendyk JP.

J Biochem Mol Toxicol. 2017 Jan;31(1):1-7. doi: 10.1002/jbt.21834. Epub 2016 Sep 8.

22.

Inhibition of PAR-4 and P2Y12 receptor-mediated platelet activation produces distinct hepatic pathologies in experimental xenobiotic-induced cholestatic liver disease.

Joshi N, Kopec AK, Ray JL, Luyendyk JP.

Toxicology. 2016 Jul 15;365:9-16. doi: 10.1016/j.tox.2016.07.021. Epub 2016 Jul 27.

23.

Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.

Brunetti L, Sanchez-Catanese B, Kagan L, Wen X, Liu M, Buckley B, Luyendyk JP, Aleksunes LM.

Thromb J. 2016 May 6;14:10. doi: 10.1186/s12959-016-0084-2. eCollection 2016.

24.

Role of Fibrin(ogen) in Progression of Liver Disease: Guilt by Association?

Kopec AK, Luyendyk JP.

Semin Thromb Hemost. 2016 Jun;42(4):397-407. doi: 10.1055/s-0036-1579655. Epub 2016 May 4. Review.

25.

Role of hemostatic factors in hepatic injury and disease: animal models de-liver.

Kopec AK, Joshi N, Luyendyk JP.

J Thromb Haemost. 2016 Jul;14(7):1337-49. doi: 10.1111/jth.13327. Epub 2016 May 10. Review.

26.

Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism.

Joshi N, Kopec AK, Ray JL, Cline-Fedewa H, Nawabi A, Schmitt T, Nault R, Zacharewski TR, Rockwell CE, Flick MJ, Luyendyk JP.

Blood. 2016 Jun 2;127(22):2751-62. doi: 10.1182/blood-2015-09-670703. Epub 2016 Feb 26.

27.

Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis.

Kong B, Zhu Y, Li G, Williams JA, Buckley K, Tawfik O, Luyendyk JP, Guo GL.

Am J Physiol Gastrointest Liver Physiol. 2016 Mar 1;310(5):G295-302. doi: 10.1152/ajpgi.00134.2015. Epub 2016 Jan 7.

28.

RNA Sequencing Identifies Novel Translational Biomarkers of Kidney Fibrosis.

Craciun FL, Bijol V, Ajay AK, Rao P, Kumar RK, Hutchinson J, Hofmann O, Joshi N, Luyendyk JP, Kusebauch U, Moss CL, Srivastava A, Himmelfarb J, Waikar SS, Moritz RL, Vaidya VS.

J Am Soc Nephrol. 2016 Jun;27(6):1702-13. doi: 10.1681/ASN.2015020225. Epub 2015 Oct 8.

29.

Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury.

Rautou PE, Tatsumi K, Antoniak S, Owens AP 3rd, Sparkenbaugh E, Holle LA, Wolberg AS, Kopec AK, Pawlinski R, Luyendyk JP, Mackman N.

J Hepatol. 2016 Jan;64(1):53-9. doi: 10.1016/j.jhep.2015.08.017. Epub 2015 Aug 29.

30.

Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice.

Miyakawa K, Joshi N, Sullivan BP, Albee R, Brandenberger C, Jaeschke H, McGill MR, Scott MA, Ganey PE, Luyendyk JP, Roth RA.

Blood. 2015 Oct 8;126(15):1835-43. doi: 10.1182/blood-2014-09-598656. Epub 2015 Jul 15.

31.

A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development.

Ellery PE, Maroney SA, Cooley BC, Luyendyk JP, Zogg M, Weiler H, Mast AE.

Blood. 2015 Jun 25;125(26):4078-84. doi: 10.1182/blood-2015-03-633958. Epub 2015 May 7.

32.

Coagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice.

Joshi N, Kopec AK, O'Brien KM, Towery KL, Cline-Fedewa H, Williams KJ, Copple BL, Flick MJ, Luyendyk JP.

J Thromb Haemost. 2015 Jan;13(1):57-71. doi: 10.1111/jth.12770. Epub 2014 Dec 11.

33.

Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.

Kopec AK, Joshi N, Towery KL, Kassel KM, Sullivan BP, Flick MJ, Luyendyk JP.

J Pharmacol Exp Ther. 2014 Nov;351(2):288-97. doi: 10.1124/jpet.114.218545. Epub 2014 Aug 19.

34.

Toxicogenomic analysis reveals profibrogenic effects of trichloroethylene in autoimmune-mediated cholangitis in mice.

Kopec AK, Sullivan BP, Kassel KM, Joshi N, Luyendyk JP.

Toxicol Sci. 2014 Oct;141(2):515-23. doi: 10.1093/toxsci/kfu148. Epub 2014 Jul 23.

35.

Fas-induced apoptosis increases hepatocyte tissue factor procoagulant activity in vitro and in vivo.

Lopez M, Kopec AK, Joshi N, Geddings JE, Cline H, Towery KL, Rockwell CE, Mackman N, Luyendyk JP.

Toxicol Sci. 2014 Oct;141(2):453-64. doi: 10.1093/toxsci/kfu139. Epub 2014 Jul 11.

36.

H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice.

Raveendran VV, Kassel KM, Smith DD, Luyendyk JP, Williams KJ, Cherian R, Reed GA, Flynn CA, Csanaky IL, Lickteig AL, Pratt-Hyatt MJ, Klaassen CD, Dileepan KN.

Am J Physiol Gastrointest Liver Physiol. 2014 Jul 15;307(2):G219-28. doi: 10.1152/ajpgi.00027.2014. Epub 2014 May 22.

37.

Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy.

Ni HM, Woolbright BL, Williams J, Copple B, Cui W, Luyendyk JP, Jaeschke H, Ding WX.

J Hepatol. 2014 Sep;61(3):617-25. doi: 10.1016/j.jhep.2014.04.043. Epub 2014 May 9.

38.

Coagulation in liver toxicity and disease: role of hepatocyte tissue factor.

Kopec AK, Luyendyk JP.

Thromb Res. 2014 May;133 Suppl 1:S57-9. doi: 10.1016/j.thromres.2014.03.023. Review.

39.

Hepatic stellate cells orchestrate clearance of necrotic cells in a hypoxia-inducible factor-1α-dependent manner by modulating macrophage phenotype in mice.

Mochizuki A, Pace A, Rockwell CE, Roth KJ, Chow A, O'Brien KM, Albee R, Kelly K, Towery K, Luyendyk JP, Copple BL.

J Immunol. 2014 Apr 15;192(8):3847-3857. doi: 10.4049/jimmunol.1303195. Epub 2014 Mar 17.

40.

The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury.

Joshi N, Kopec AK, Towery K, Williams KJ, Luyendyk JP.

J Pharmacol Exp Ther. 2014 Jun;349(3):383-92. doi: 10.1124/jpet.113.210880. Epub 2014 Mar 14.

41.

Circulating microparticle tissue factor activity is increased in patients with cirrhosis.

Rautou PE, Vion AC, Luyendyk JP, Mackman N.

Hepatology. 2014 Nov;60(5):1793-5. doi: 10.1002/hep.27033. Epub 2014 Oct 1. No abstract available.

42.

Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Li G, Zhu Y, Tawfik O, Kong B, Williams JA, Zhan L, Kassel KM, Luyendyk JP, Wang L, Guo GL.

Am J Physiol Gastrointest Liver Physiol. 2013 Dec;305(11):G829-37. doi: 10.1152/ajpgi.00155.2013. Epub 2013 Oct 3.

43.

IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis.

O'Brien KM, Allen KM, Rockwell CE, Towery K, Luyendyk JP, Copple BL.

Am J Pathol. 2013 Nov;183(5):1498-1507. doi: 10.1016/j.ajpath.2013.07.019. Epub 2013 Sep 5.

44.

Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.

Li G, Kong B, Zhu Y, Zhan L, Williams JA, Tawfik O, Kassel KM, Luyendyk JP, Wang L, Guo GL.

Toxicol Appl Pharmacol. 2013 Oct 15;272(2):299-305. doi: 10.1016/j.taap.2013.06.016. Epub 2013 Jun 26.

45.

Keap1 knockdown increases markers of metabolic syndrome after long-term high fat diet feeding.

More VR, Xu J, Shimpi PC, Belgrave C, Luyendyk JP, Yamamoto M, Slitt AL.

Free Radic Biol Med. 2013 Aug;61:85-94. doi: 10.1016/j.freeradbiomed.2013.03.007. Epub 2013 Mar 16.

46.

PAR-1 contributes to the innate immune response during viral infection.

Antoniak S, Owens AP 3rd, Baunacke M, Williams JC, Lee RD, Weithäuser A, Sheridan PA, Malz R, Luyendyk JP, Esserman DA, Trejo J, Kirchhofer D, Blaxall BC, Pawlinski R, Beck MA, Rauch U, Mackman N.

J Clin Invest. 2013 Mar;123(3):1310-22. doi: 10.1172/JCI66125. Epub 2013 Feb 8.

47.

Hepatocyte tissue factor activates the coagulation cascade in mice.

Sullivan BP, Kopec AK, Joshi N, Cline H, Brown JA, Bishop SC, Kassel KM, Rockwell C, Mackman N, Luyendyk JP.

Blood. 2013 Mar 7;121(10):1868-74. doi: 10.1182/blood-2012-09-455436. Epub 2013 Jan 10.

48.

Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Kassel KM, Sullivan BP, Cui W, Copple BL, Luyendyk JP.

Am J Pathol. 2012 Oct;181(4):1287-95. doi: 10.1016/j.ajpath.2012.06.011. Epub 2012 Jul 26.

49.

Fibrin(ogen)-independent role of plasminogen activators in acetaminophen-induced liver injury.

Sullivan BP, Kassel KM, Jone A, Flick MJ, Luyendyk JP.

Am J Pathol. 2012 Jun;180(6):2321-9. doi: 10.1016/j.ajpath.2012.02.011. Epub 2012 Apr 13.

50.

Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Owens AP 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, Luyendyk JP, Moriarty PM, Nagarajan S, Furie BC, Furie B, Johns DG, Temel RE, Mackman N.

J Clin Invest. 2012 Feb;122(2):558-68. doi: 10.1172/JCI58969. Epub 2012 Jan 3.

Supplemental Content

Loading ...
Support Center